Hair Loss Pills Are Changing How Men Think About Masculinity

Fifty million American men live with androgenetic alopecia, the genetic and hormonal process that thins and retreats the hairline over decades. By age 50, roughly half of all men notice significant hair loss, a figure that climbs to around 80% by age 70. For most of the 20th century, the cultural script was simple: you went bald, you accepted it, and you moved on. That script is being rewritten — not by a new surgery or an experimental gene therapy, but by a daily pill that has been sitting on pharmacy shelves for more than 25 years.

From prostate drug to cultural phenomenon

For decades, millions of men around the world have turned to finasteride, sold under its best-known brand name Propecia, to slow hair loss. But what began as a prostate medication has become one of the most discussed drugs in men's health. Originally developed at the 5mg dose (sold as Proscar) to treat benign prostatic hyperplasia, an enlarged prostate, it was later approved by the FDA at a 1mg dose specifically for male pattern baldness. The mechanism is precise: finasteride blocks the 5-alpha-reductase enzyme, preventing testosterone from converting into dihydrotestosterone (DHT), the androgen responsible for shrinking hair follicles. A daily dose reduces scalp DHT levels by approximately 70%.

The numbers tell a story of accelerating demand. US finasteride prescriptions have surged 200% over seven years, driven in large part by the proliferation of telehealth platforms that allow men to get a diagnosis and a prescription entirely online. The global finasteride market was valued at USD 130.8 million in 2025 and is projected to grow to USD 165.8 million by 2035, at a compound annual growth rate of 2.4%. The hair loss application alone accounts for roughly 42.6% of that market share.

The telehealth engine

The delivery mechanism has changed as much as the demand. Companies like Hims, Keeps, and Roman have built subscription businesses around the premise that men will pay for convenience and privacy. These businesses employ doctors who can diagnose hair loss patients via online consultations, then prescribe generic finasteride and other oral and topical hair growth medications, delivering the drugs directly to the patient's door. Generic finasteride is available for around $60 for a 90-day supply. Walgreens and GoodRx now offer their own virtual healthcare pathways to the same prescription.

The scale is striking. A retrospective analysis of real-world data found that 638,629 male patients received a prescription for a compounded topical finasteride and minoxidil product between April 2021 and April 2025. Of those who completed a follow-up check-in, 80.4% reported being satisfied with their treatment. The ease of access has also shifted the age profile of users. As one dermatologist told NBC News, "People are interested in treating it a little bit younger than what I saw before." Finasteride is now increasingly prescribed even before visible baldness begins, as a prophylactic measure for men in their twenties who have a family history of hair loss.

Why now: the masculinity shift

That earlier uptake reflects something more than medical pragmatism. It signals a genuine cultural renegotiation of what it means to be a man who cares about his appearance. For generations, spending money or time on hair was coded as vanity, or worse, insecurity. A 2025 systematic review and meta-analysis in Frontiers in Psychiatry confirmed that the visible changes in appearance caused by androgenetic alopecia can create significant cognitive dissonance in how patients perceive themselves, leading to heightened concerns about appearance and the potential stigma associated with hair loss. This heightened self-awareness and fear of negative judgment can significantly impact an individual's social functioning and quality of life.

The stigma, it turns out, was carefully cultivated. An investigation by CBC/Radio-Canada found that Merck, the maker of Propecia, invested heavily in the stigmatization of baldness through mainstream advertising campaigns and through more covert means. Social media has now inverted that dynamic: instead of pharmaceutical ads manufacturing anxiety, men are sharing their own hair loss journeys and treatment progress on platforms including Reddit's active Tressless community, where before-and-after photos and drug regimen discussions normalize treatment-seeking in a way no broadcast campaign ever could.

What the evidence actually shows

Finasteride is not a cure, and it is not without controversy. Results take between 3 and 12 months to appear, and the drug is best suited for early-stage hair loss, where it can preserve and thicken existing hair rather than restore what is already gone. Adherence matters enormously: stopping the medication reverses its benefits, typically within 12 months. Because topical regimens have shown suboptimal adherence in clinical practice, the simple daily pill format has an inherent practical advantage.

The side effect profile is where the conversation gets complicated. Side effects include decreased libido, erectile dysfunction, ejaculation issues, and mood changes; these are rare and often temporary for most users. The real-world data supports relative safety at scale: of the 638,629 patients in the PMC retrospective, only 2.7% of those who completed follow-up reported experiencing a side effect, and just 0.04% sent their care team a message about a serious concern.

But the tail risk is real and has recently received formal regulatory attention. In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect of finasteride and the related drug dutasteride, with the majority of reports involving patients taking the 1mg dosage typically prescribed for hair loss. The FDA separately warned in April 2025 about unapproved topical finasteride sprays being sold online, noting reports of sexual side effects, depression, and suicidal ideation, as well as risks to women of childbearing age, since finasteride can cause birth defects in male fetuses.

Post-finasteride syndrome: the contested frontier

For a minority of men, the problems do not stop when the prescription does. Post-Finasteride Syndrome (PFS) describes a constellation of persistent sexual, neurological, psychological, and emotional symptoms that continue months or years after discontinuing the drug. Finasteride's controversy stems from reports of persistent adverse effects, including sexual dysfunction and psychiatric symptoms, following its use; while many tolerate the drug well, a minority develop post-finasteride syndrome, sparking debate about causality and risk. The condition lacks a definitive diagnostic test and remains contested in the medical literature, but patient advocacy groups and some researchers argue that its existence is being systematically underappreciated, particularly given how quickly online platforms are now scaling prescriptions with limited follow-up infrastructure.

What to ask your doctor

The 200% prescription surge is happening in a system where the distance between "complete an online questionnaire" and "receive a 90-day supply" has collapsed to minutes. That speed is genuinely useful for millions of men with a straightforward presentation and no complicating factors. It demands, however, that anyone considering finasteride go into that conversation, whether virtual or in-person, with specific questions:

• Am I a good candidate? Finasteride works best for early-stage androgenetic alopecia. The earlier the intervention, the more hair there is to preserve.
• What is my personal risk for sexual side effects? Men with existing sexual dysfunction or depression may face elevated risks and deserve individualized counseling.
• Should I use topical rather than oral finasteride? Emerging evidence suggests topical formulations can produce comparable results with lower systemic DHT suppression, potentially reducing the risk of systemic side effects.
• How long should I trial the medication before assessing response? Understanding the 3-to-12-month window sets realistic expectations and prevents premature discontinuation.
• What are the warning signs I should act on immediately? Any onset of depression, suicidal ideation, or persistent sexual dysfunction warrants prompt contact with a healthcare provider, not just a note in a telehealth app.
• What happens if I stop taking it? Hair loss typically resumes. This is a long-term commitment, and that context matters before starting.
• Are there interactions with my current medications or health conditions? Finasteride affects hormone metabolism in ways that can intersect with other treatments.
• Is combination therapy appropriate for my case? A 2025 retrospective evaluation found that combining oral finasteride with minoxidil produced meaningful improvements in androgenetic alopecia, and dermatologists increasingly favor this dual approach.

The larger picture

The story of finasteride is ultimately about what happens when a long-stigmatized health concern collides with frictionless access, social media normalization, and a generation of men who grew up more willing to discuss insecurity than their fathers were. The proliferation of telehealth services is the single biggest driver of the surge in young and middle-aged men trying finasteride for the first time. That is, on balance, a democratizing development. But democratizing access to a drug with a contested safety profile in a system optimized for speed over depth of consent creates accountability gaps that regulators, platforms, and clinicians have not yet fully closed. The pill is changing men's relationship to appearance and vulnerability. Whether the healthcare infrastructure around it matures fast enough to match that shift is the harder question.